Area of research
Hematology · Genetics
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Hemoglobinopathies and Related Disorders, Acute Myeloid Leukemia Research, and Acute Lymphoblastic Leukemia research.
Cryopreservation of Hemopoietic Cells for Allotransplant: Altered Immune Cell Subsets and Clinical Implications.
Targeted Screening to Predict <i>Magnusiomyces</i> Infections in Hematopoietic Cell Transplant Recipients: Evidence from an Outbreak Setting.
A Modified-Delphi Consensus on the Management of Patients with FLT3-Mutated AML.
Immunogenetic Architecture of Chronic Lymphocytic Leukemia at Early Stage: Insights from the O-CLL1 Cohort.
Intraclonal Enrichment of IL-23 Receptor Complex Expression in the Proliferative Fraction of Chronic Lymphocytic Leukemia.
An extraction pipeline for analysis of hematopoietic stem cell transplantation data.
Intraclonal Enrichment of IL-23 Receptor Complex Expression in the Proliferative Fraction of Chronic Lymphocytic Leukemia
Critical role of cascade screening in thalassemia control
The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT
The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT.
Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations
Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial.
Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations.
Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis.
How I manage iron overload in the hematopoietic cell transplantation setting.
NAD+ metabolism restriction boosts high-dose melphalan efficacy in patients with multiple myeloma.
Pre-engraftment bloodstream infection after allogeneic haematopoietic cell transplant: 18-year trends in aetiology, resistance and mortality.
Targeting the p53/xCT/GSH Axis with PRIMA-1<sup>Met</sup> Combined with Sulfasalazine Shows Therapeutic Potential in Chronic Lymphocytic Leukemia.
Long-Term Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: An Italian Multicenter Collaborative Study
Advancing the Integration of ‘Basic/Fundamental’ and Translational Cellular and Gene Therapy Science within the EBMT: Accelerating the Pathway to Progress
"Learn and Know" in the era of gene addition/gene editing based approaches for sickle cell disease: The EHA-EBMT consensus paper.
Haploidentical versus matched unrelated donor hematopoietic cell transplantation for adult patients with refractory/relapsed acute lymphoblastic leukemia: a study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi.
Advancing the Integration of 'Basic/Fundamental' and Translational Cellular and Gene Therapy Science within the EBMT: Accelerating the Pathway to Progress.
The need for a subsequent HCT is a late & continuous risk and with significant impact in overall survival in haemoaglobinopathies: Real-world data from 2000–2022. an analysis of the european society for blood and marrow transplantation (EBMT) hemoglobinopathy working party.
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis)
Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT
Vamifeport: Monography of the First Oral Ferroportin Inhibitor.
Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO study.
Haploidentical bone marrow transplantation for AML in remission after TBF conditioning: a long-term follow-up.